GGrantIndex
Sort

48,018 grants matching immunotherapy

Lab Research Training in Pediatric Oncology-Hematology

$666,679
Alan D Friedman · Johns Hopkins University · T32 · FY2025 · CA

Transcriptional Regulation of human natural killer cell function

$666,567
Timothy E O'Sullivan · University Of California Los Angeles · R01 · FY2025 · AI

Mechanism of cell uptake for pathogenic tau seeds

$666,475
Marc I Diamond · Ut Southwestern Medical Center · R01 · FY2025 · AG

POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma

$666,466
Diane M Simeone · New York University School Of Medicine · R01 · FY2022 · CA

CANCER AND LEUKEMIA GROUP B

$666,421
Brigham And Women'S Hospital · U10 · FY2001 · CA

Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials

$666,397
Andre Rogatko · Cedars-Sinai Medical Center · U01 · FY2020 · CA

Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials

$666,397
Mourad Tighiouart · Cedars-Sinai Medical Center · U01 · FY2021 · CA

Immune correlates of acute HBV recovery with and without HIV

$666,387
Chloe L Thio · Johns Hopkins University · R01 · FY2016 · AI

Nanotherapeutic strategies for the treatment of chronic Chagas Disease

$666,319
Evan Alexander Scott · University Of Virginia · R01 · FY2025 · HL

Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor

$666,296
Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy

$666,104
Youngho Seo · University Of California, San Francisco · R01 · FY2024 · HL

Alpha-Emitter Therapy of Osteosarcoma

$666,045
Dara L Kraitchman · Johns Hopkins University · R01 · FY2025 · CA

Molecular Allergy

$666,036
Geoffrey Mueller · National Institute Of Environmental Health Sciences · ZIA · FY2020 · ES

Variation in tumor-associated immune profiles and colorectal cancer outcomes

$665,918
Stephanie L. Schmit · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · CA

An urinary drug disposing approach for treatment of bladder Cancer

$665,916
Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA

Frequency and phenotype of Fel d 1-specific T cells after peptide therapy

$665,907
Mark Larche · Mcmaster University · U19 · FY2016 · AI

Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer

$665,878
Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2021 · CA

Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma

$665,841
Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA

Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma

$665,839
Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA

Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma

$665,839
Christine Brown · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA

Using artificial intelligence to discover spatial, genomic, and pathologic biomarkers to guide and augment immune checkpoint inhibitor therapy for gastric cancer

$665,617
Sam C. Wang · Ut Southwestern Medical Center · R01 · FY2025 · CA

A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity

$665,532
Catherine Sibyl Diefenbach · New York University School Of Medicine · R01 · FY2024 · CA

Dissecting the role of CD8+ T cells in atherosclerosis

$665,467
Chiara Giannarelli · New York University School Of Medicine · R01 · FY2023 · HL

Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer

$665,456
Meghan E. Sise · Massachusetts General Hospital · R01 · FY2025 · DK

Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA

$665,413
Aadel Chaudhuri · Mayo Clinic Rochester · R01 · FY2025 · CA